MedTrace Logo

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

NCT07121972 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-11-06

No results posted yet for this study

Summary

This is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.

Conditions

  • Cancer Risk
  • Breast Cancer Risk

Interventions

PROCEDURE

Magnetic resonance imaging (MRI)

Undergo Magnetic resonance (MR) imaging

DEVICE

Artificial Intelligence (AI)

AI applied to MRI images

Sponsors & Collaborators

Principal Investigators

  • Maggie Chung, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
89 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-03
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07121972 on ClinicalTrials.gov